Headline article at the Fool today:
Organovo (NYSEMKT: ONVO ) has made headlines this year for its revolutionary tissue engineering platform, more commonly referred to as 3-D bioprinting. The company can add a tremendous amount of value to the pharmaceutical industry in the drug discovery process in the next several years and is targeting longer-term revenue streams with its ability to grow cancer tissues and human organs for transplantation. However, focusing solely on these great advances sells short the broader impacts that industrial tissue engineering and 3-D bioprinting platforms can have on society. What are some less-publicized applications within reach of the disruptive technologies?...
RTWTIn the future, 3-D printers will download vaccines and medications from the Internet and then use standard chemical building blocks to print doses in your own home.